{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:16:57Z","timestamp":1776777417033,"version":"3.51.2"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","funder":[{"DOI":"10.13039\/100001063","name":"Crohn\u2019s and Colitis Foundation of America","doi-asserted-by":"publisher","award":["3830"],"award-info":[{"award-number":["3830"]}],"id":[{"id":"10.13039\/100001063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Millennium Pharmaceuticals"},{"name":"Takeda and Osiris"},{"name":"Prometheus Laboratories"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3,1]]},"DOI":"10.1093\/ecco-jcc\/jju026","type":"journal-article","created":{"date-parts":[[2014,12,25]],"date-time":"2014-12-25T00:35:17Z","timestamp":1419467717000},"page":"266-275","source":"Crossref","is-referenced-by-count":52,"title":["High-Dose Infliximab Therapy in Crohn\u2019s Disease: Clinical Experience, Safety,\n          and Efficacy"],"prefix":"10.1093","volume":"9","author":[{"given":"Steven A","family":"Hendler","sequence":"first","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}]},{"given":"Benjamin L","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}]},{"given":"Bruce E","family":"Sands","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}]},{"given":"Lloyd","family":"Mayer","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA."}]},{"given":"Shradha","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA."}]}],"member":"286","published-online":{"date-parts":[[2015,2,13]]},"reference":[{"key":"2019042410531200500_CIT0001","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised\n            trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"2019042410531200500_CIT0002","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis\n            factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"2019042410531200500_CIT0003","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s\n            disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"2019042410531200500_CIT0004","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1365-2036.2007.03548.x","article-title":"Infliximab dose escalation vs. initiation of adalimumab\n            for loss of response in Crohn\u2019s disease: a cost-effectiveness analysis","volume":"26","author":"Kaplan","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"2019042410531200500_CIT0005","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ibd.20177","article-title":"Infliximab dose intensification in Crohn\u2019s\n            disease","volume":"13","author":"Regueiro","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"2019042410531200500_CIT0006","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/MCG.0b013e3181ebaef9","article-title":"Long-term durability of infliximab treatment in Crohn\u2019s disease and\n            efficacy of dose \u2018escalation\u2019 in patients losing response","volume":"45","author":"Chaparro","year":"2011","journal-title":"J\n            Clin Gastroenterol"},{"key":"2019042410531200500_CIT0007","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/ibd.22902","article-title":"Doubling the infliximab dose versus halving the infusion intervals in\n            Crohn\u2019s disease patients with loss of response","volume":"18","author":"Katz","year":"2012","journal-title":"Inflamm Bowel\n            Dis"},{"key":"2019042410531200500_CIT0008","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody\n            concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J\n            Gastroenterol"},{"key":"2019042410531200500_CIT0009","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1572-0241.2001.03671.x","article-title":"Practice Parameters Committee of the American College of\n            Gastroenterology. Management of Crohn\u2019s disease in adults","volume":"96","author":"Hanauer","year":"2001","journal-title":"Am J\n            Gastroenterol"},{"key":"2019042410531200500_CIT0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jim.2012.06.002","article-title":"Development and validation of a homogenous mobility shift assay for the\n            measurement of infliximab and antibodies-to-infliximab levels in patient\n            serum","volume":"382","author":"Wang","year":"2012","journal-title":"J Immunol\n            Methods"},{"key":"2019042410531200500_CIT0011","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cgh.2012.06.032","article-title":"Therapeutic drug monitoring of tumor necrosis factor\n            antagonists in inflammatory bowel disease","volume":"10","author":"Ordas","year":"2012","journal-title":"Clin Gastroenterol\n            Hepatol"},{"key":"2019042410531200500_CIT0012","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large\n            center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"2019042410531200500_CIT0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2036.2011.04679.x","article-title":"Review article: Causative factors and the clinical\n            management of patients with Crohn\u2019s disease who lose response to anti-TNF-alpha\n            therapy","volume":"34","author":"Danese","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2019042410531200500_CIT0014","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s\n            disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"2019042410531200500_CIT0015","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome\n            after scheduled maintenance treatment for Crohn\u2019s disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin\n            Gastroenterol Hepatol"},{"key":"2019042410531200500_CIT0016","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00535-013-0829-7","article-title":"Relationship between serum infliximab trough levels and endoscopic\n            activities in patients with Crohn\u2019s disease under scheduled maintenance\n            treatment","volume":"49","author":"Imaeda","year":"2014","journal-title":"J Gastroenterol"},{"key":"2019042410531200500_CIT0017","first-page":"A1","article-title":"Randomised controlled trial of drug level versus clinically based dosing of\n            infliximab maintenance therapy in IBD: Final results of the TAXIT study","volume":"1S","author":"Casteele","year":"2013","journal-title":"United European Gastroenterology\n            Journal"},{"key":"2019042410531200500_CIT0018","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s\n            disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"2019042410531200500_CIT0019","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than\n            5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J\n            Gastroenterol"},{"key":"2019042410531200500_CIT0020","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody)\n            versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a\n            randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"2019042410531200500_CIT0021","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.cgh.2014.01.033","article-title":"Early trough levels and antibodies to infliximab predict safety and success\n            of reinitiation of infliximab therapy","volume":"12","author":"Baert","year":"2014","journal-title":"Clin Gastroenterol\n            Hepatol"},{"key":"2019042410531200500_CIT0022","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cgh.2011.02.008","article-title":"Levels of C-reactive protein are associated with response to infliximab\n            therapy in patients with Crohn\u2019s disease","volume":"9","author":"Jurgens","year":"2011","journal-title":"Clin Gastroenterol\n            Hepatol"},{"key":"2019042410531200500_CIT0023","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.crohns.2013.07.005","article-title":"High C-reactive protein in Crohn\u2019s disease patients predicts nonresponse to\n            infliximab treatment","volume":"8","author":"Magro","year":"2014","journal-title":"J Crohns\n          Colitis"},{"key":"2019042410531200500_CIT0024","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2217\/imt.12.114","article-title":"Anti-TNF-alpha biotherapies: perspectives for\n            evidence-based personalized medicine","volume":"4","author":"Bendtzen","year":"2012","journal-title":"Immunotherapy"},{"key":"2019042410531200500_CIT0025","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/ajg.2014.146","article-title":"Development of an algorithm incorporating pharmacokinetics of adalimumab in\n            inflammatory bowel diseases","volume":"109","author":"Roblin","year":"2014","journal-title":"Am J\n            Gastreoenterol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/9\/3\/266\/28518065\/jju026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T10:53:31Z","timestamp":1556103211000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/9\/3\/266\/361857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,13]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,2,13]]},"published-print":{"date-parts":[[2015,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jju026","relation":{},"ISSN":["1876-4479","1873-9946"],"issn-type":[{"value":"1876-4479","type":"electronic"},{"value":"1873-9946","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,3]]},"published":{"date-parts":[[2015,2,13]]}}}